Daclizumab

• Daclizumab is a humanized monoclonal antibody designed to modulate the immune system.
• Its mechanism involves binding to the CD25 subunit of the IL-2 receptor, inhibiting T-cell activation.
• It was previously approved for relapsing forms of multiple sclerosis but was voluntarily withdrawn due to serious safety concerns.
• Significant side effects included inflammatory brain disorders, severe liver injury, and serious infections.
• Patients should discuss all potential risks and benefits of similar treatments with their healthcare provider.

What is Daclizumab: Drug Overview

Daclizumab is a humanized monoclonal antibody specifically engineered to target the CD25 subunit of the interleukin-2 (IL-2) receptor, which is predominantly expressed on activated T-lymphocytes. This drug was designed to modulate the immune system, primarily for conditions where an overactive immune response contributes to disease pathology. Historically, it received approval in several regions for the treatment of relapsing forms of multiple sclerosis (RMS). However, due to serious safety concerns, including inflammatory brain disorders and severe liver injury, it was voluntarily withdrawn from the global market in 2018. Comprehensive Daclizumab drug information is crucial for healthcare professionals and patients to understand its past role and the significant reasons that led to its withdrawal.

Daclizumab Mechanism of Action and Uses

The Daclizumab mechanism of action involves its high-affinity binding to CD25, also known as the alpha subunit of the high-affinity IL-2 receptor. By selectively binding to CD25, Daclizumab effectively prevents interleukin-2 (IL-2) from attaching to its receptor on the surface of activated T-cells. This critical blockade inhibits IL-2-mediated signaling, a process vital for the proliferation, differentiation, and survival of activated T-lymphocytes. Consequently, Daclizumab reduces the number of these activated T-cells, thereby dampening the overall immune response.

Regarding what Daclizumab was used for, its primary clinical application was in the treatment of relapsing forms of multiple sclerosis (RMS). In RMS, the immune system mistakenly attacks the myelin sheath protecting nerve fibers, leading to demyelination and subsequent neurological symptoms. Daclizumab aimed to reduce the frequency of relapses and slow the progression of disability by modulating this autoimmune attack. It was also explored for other autoimmune conditions, such as uveitis, but its most prominent use was focused on MS before its market withdrawal.

Daclizumab Side Effects and Important Safety Information

While demonstrating efficacy in some patients, Daclizumab side effects were a major concern, ultimately leading to its voluntary market withdrawal. Patients treated with Daclizumab experienced a range of adverse events, some of which were serious and life-threatening.

Key safety concerns and reported adverse effects included:

• Serious inflammatory brain disorders: Cases of encephalitis and meningoencephalitis, some with fatal outcomes, were reported. These conditions involve inflammation of the brain and its surrounding membranes.
• Severe liver injury: This included instances of liver failure requiring transplantation, with some cases resulting in death. Regular monitoring of liver function was a critical safety measure.
• Serious infections: Patients had an increased risk of various infections, including opportunistic infections, due to the immunosuppressive nature of the drug.
• Skin reactions: Severe skin reactions, such as dermatitis, eczema, and rashes, were frequently observed.
• Autoimmune conditions: New or worsening autoimmune conditions, including non-infectious colitis and autoimmune thyroiditis, were noted in some individuals.

Due to these significant risks, particularly the inflammatory brain disorders and severe liver injury, Daclizumab was voluntarily withdrawn from the market by its manufacturers in March 2018. This decision highlighted the critical importance of continuous pharmacovigilance and a thorough assessment of the benefit-risk profile for all medications. Patients who were receiving Daclizumab at the time of its withdrawal were strongly advised to consult their healthcare providers immediately to transition to alternative treatments and undergo monitoring for potential lingering adverse effects.